SequelSEC

Immix Biopharma, Inc. IMMX

Pharmaceutical Preparations · CIK 0001873835 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$12.46M
Fiscal year ended 2026-06-30
Free cash flow
-$11.76M
Fiscal year ended 2026-06-30

Immix Biopharma, Inc. (IMMX) reported net income of -$11.56M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Immix Biopharma, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Immix Biopharma, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$12.46MUnavailableUnavailable-$7.66M-$6.72MUnavailable-$4.99M-$7.39M-$4.70M-$5.59M
Net income-$11.56MUnavailableUnavailable-$7.59M-$6.62MUnavailable-$4.81M-$7.15M-$4.39M-$5.26M
Research & development$5.33MUnavailableUnavailable$4.58M$3.97MUnavailable$1.37M$4.45M$2.22M$3.25M
Weighted-average diluted sharesshares 63.77MUnavailableUnavailableshares 31.93Mshares 29.98MUnavailableUnavailableshares 29.42Mshares 28.79Mshares 23.44M
Pretax income-$11.54MUnavailableUnavailable-$7.58M-$6.61MUnavailable-$4.80M-$7.14M-$4.40M-$5.32M
Income tax expense$14.32KUnavailableUnavailable$7.72K$8.91KUnavailable$10.78K$11.14K$10.27K$8.84K
Diluted EPS$-0.18UnavailableUnavailable$-0.24$-0.22UnavailableUnavailable$-0.24$-0.15$-0.22
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$7.12MUnavailableUnavailable$3.08M$2.75MUnavailable$3.61M$2.95M$2.48M$2.34M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Immix Biopharma, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$225.49MUnavailableUnavailable$15.95M$11.64MUnavailable$17.68M$19.69M$23.98M$29.32M
Total assets$239.11MUnavailableUnavailable$20.08M$15.64MUnavailable$22.95M$25.14M$28.84M$34.35M
Current assets$233.79MUnavailableUnavailable$16.58M$12.33MUnavailable$20.20M$22.76M$27.33M$32.92M
Total liabilities$10.19MUnavailableUnavailable$11.82M$10.98MUnavailable$9.70M$7.59M$4.94M$6.72M
Current liabilities$9.30MUnavailableUnavailable$10.85M$10.01MUnavailable$8.69M$6.56M$3.90M$5.66M
Total equity incl. NCI$228.92MUnavailableUnavailable$8.26M$4.65MUnavailable$13.25M$17.55M$23.89M$27.63M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$5.28MUnavailableUnavailable$7.05M$6.61MUnavailable$5.39M$3.29M$2.35M$3.51M

Cash flow

Immix Biopharma, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$11.74MUnavailableUnavailable-$5.91M-$5.31MUnavailable-$1.48M-$4.04M-$5.26M-$3.83M
Capital expenditures$21.04KUnavailableUnavailable$372.46K$127.63KUnavailable$507.15K$271.54K$97.07K$301.91K
Investing cash flow$2.67MUnavailableUnavailable-$372.46K-$127.63KUnavailable-$507.15K-$271.54K-$97.07K-$301.91K
Financing cash flow$155.28MUnavailableUnavailable$10.61MUnavailableUnavailable$0$0$0$15.95M
Net change in cash$146.24MUnavailableUnavailable$4.31M-$4.28MUnavailable-$2.01M-$4.28M-$5.34M$11.81M
Stock-based compensation$978.14KUnavailableUnavailable$470.47K$532.25KUnavailable$705.65K$733.81K$637.85K$943.26K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Immix Biopharma, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$11.76MUnavailableUnavailable-$6.28M-$5.44MUnavailable-$1.98M-$4.31M-$5.35M-$4.13M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio25.13xUnavailableUnavailable1.53x1.23xUnavailable2.33x3.47x7.00x5.82x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IMMX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K/A · Filed 2026-03-27View SEC filing
10-K · Filed 2026-03-25View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

6 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationinconsistent2026-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2026-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-12-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-12-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.